tbuckley/cabot-search huggingface dataset:
In patients with hypertension, taking all BP-lowering drugs at bedtime vs in the morning reduced CV events
Authors: Paul Glasziou, Jenny Doust
Journal: Annals of Internal Medicine (2020)

Source Citation Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2019. [Epub ahead of print]. 31641769
Cambridge Translational Cancer Research Ovarian Study 01 (CTCR-OV01): Expression profiling of advanced epithelial ovarian cancer (EOC) to predict chemotherapy response. A randomised phase II trial design with prospective translational endpoints
Authors: H. M. Earl, A. Ahmed, A. Vallier, H. Hatcher, C. A. Parkinson, M. Iddawela, J. Latimer, R. Crawford, J. D. Brenton
Journal: Journal of Clinical Oncology (2006)

15018 Methods: CTCR-OV01 is a randomised phase II neoadjuvant study in stage III-IV epithelial ovarian cancer (EOC). Patients (pts) were consented for diagnostic and fresh tissue research biopsies, and after diagnosis was confirmed, were randomised (1:1) to: Arm A: Carboplatin AUC 7 every 3 weeks (C) × 3 cycles (cy); then interval debulking surgery (IDS); then C AUC 6 with paclitaxel 175 mg/m 2 q 3w (CT) × 3 cy; and finally paclitaxel 175 mg/m 2 q 3w (T) × 3 cy. Arm B: T × 3 cy; IDS; CT × 3 cy; C × 3 cy. At IDS further fresh tissue samples were collected. Clinical Endpoints: (i) Partial response rate after three cycles of chemotherapy based on CA125 (CA125 RR) and CT scan (CT RR). (ii) Median progression-free survival (PFS). Translational endpoints: Candidate genes and molecular profiles as predictive markers of response/resistance to C and T. Results: Jan ‘02-Dec ‘04, 48 pts were randomised in a single centre study. 4 patients were excluded from analysis (3pts severe toxicity; 1pt incorrect histopathology), leaving 44 patients (21pts A/23 pts B). Median age 60 yr (range 36–75 yrs); 42/44 serous papillary histology; stage III/IV = 77%/23%; grade I/II/III = 2%/34%/64%. All prognostic factors were well balanced between treatment arms. Median follow-up is 22 months (IQR 17–33.5). CA125 RR to pre-operative chemotherapy was A/B = 65%/60% (p = 1). CT RR was A/B = 47%/35% (p = 0.15). CA125 RR, was significantly associated with improvement in progression-free survival (PFS) compared to non-responders (17.3 v 12.4 months; log rank test p = 0.027). Optimal debulking surgery was possible in A/B = 53%/63%. Median PFS was 14 months (m) (A/B = 13 m/14 m (p = 0.53)). Supervised analysis of Affymetrix expression data showed significant enrichment for differential extracellular gene expression in paclitaxel resistant patients. Conclusions: Prospective controlled randomized trials using neoadjuvant treatment are ideally suited for translational research in EOC and provide unique sample sets molecular analysis. No significant financial relationships to disclose.
DESCRIPTION OF LEFT VENTRICULAR STRAIN IN DANON DISEASE: INSIGHTS FROM A GLOBAL REGISTRY
Authors: Quan Bui, Gary Ma, Megan Kraushaar, Victor Escobedo, Boss Le, Liz Covarrubias, Michela Brambatti, Andrew Kahn, Chrystelle Bougault, Kimberly N. Hong, Matthew R. Taylor, Eric Adler
Journal: Journal of the American College of Cardiology (2020)
A Novel Micropeptide Encoded by Y-Linked LINC00278 Links Cigarette Smoking and AR Signaling in Male Esophageal Squamous Cell Carcinoma
Authors: Siqi Wu, Liyuan Zhang, Jieqiong Deng, Binbin Guo, Fang Li, Yirong Wang, Rui Wu, Shenghua Zhang, Jiachun Lu, Yifeng Zhou
Journal: Cancer Research (2020)

Abstract Long noncoding RNAs (lncRNA) have been shown to play critical roles in many diseases, including esophageal squamous cell carcinoma (ESCC). Recent studies have reported that some lncRNA encode functional micropeptides. However, the association between ESCC and micropeptides encoded by lncRNA remains largely unknown. In this study, we characterized a Y-linked lncRNA, LINC00278, which was downregulated in male ESCC. LINC00278 encoded a Yin Yang 1 (YY1)-binding micropeptide, designated YY1BM. YY1BM was involved in the ESCC progression and inhibited the interaction between YY1 and androgen receptor (AR), which in turn decreased expression of eEF2K through the AR signaling pathway. Downregulation of YY1BM significantly upregulated eEF2K expression and inhibited apoptosis, thus conferring ESCC cells more adaptive to nutrient deprivation. Cigarette smoking decreased m6A modification of LINC00278 and YY1BM translation. In conclusion, these results provide a novel mechanistic link between cigarette smoking and AR signaling in male ESCC progression. Significance: Posttranscriptional modification of a micropeptide-encoding lncRNA is negatively impacted by cigarette smoking, disrupting negative regulation of the AR signaling pathway in male ESCC.
Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity
Authors: Yogesh N.V. Reddy, Aruna Rikhi, Masaru Obokata, Sanjiv J. Shah, Gregory D. Lewis, Omar F. AbouEzzedine, Shannon Dunlay, Steven McNulty, Hrishikesh Chakraborty, Lynne W. Stevenson, Margaret M. Redfield, Barry A. Borlaug
Journal: European Journal of Heart Failure (2020)
Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): Pooled analysis of two randomised trials, the GERCOR/GISCAD Intergroup Study and a German Multicenter Study
Authors: C. Louvet, A. Hincke, R. Labianca, V. Heinemann
Journal: Journal of Clinical Oncology (2006)

4003 Background: Two randomized trials (GERCOR/GISCAD: gemcitabine [GEM] plus oxaliplatin versus Gem; German multicenter trial: Gem plus cisplatin versus Gem) indicated superior efficacy in terms of response rate and progression-free survival (PFS) for combined therapy. While a trend for prolonged overall survival (OS) was reported in these underpowered studies, they failed to demonstrate a significant advantage. Methods: We report a pooled analysis of both studies. Standard methods for meta-analysis based on individual patient (pt) data were used. Results: Among 503 evaluable pts, 252 received the combination therapy (GP), while 251 pts were treated with Gem single agent (G). In the GP vs G groups, an ECOG performance status = 0 was observed in 40% vs 35%, distant metastasis in 72% vs 73%, and pathological tumor grading of 3 in 34% vs 38%, respectively. A high degree of homogeneity was noted among the study groups with regard to survival data. For PFS, the pooled univariate analysis indicated a hazard ratio (HR) of 1.34 (95% CI, 1.11–1.63, p=.0030; median PFS 5.5 m vs 3.5 m) in favour of the GP-combination. The benefit of the GP-combination was greatest in the subgroup of pts with PS 0 (HR=1.56; 95% CI, 1.11–2.20, p=.013). OS was significantly superior in the GP pts (HR=1.23; 95% CI, 1.02–1.49, p=.031; median OS 8.3 m vs 6.7m). Again, pts with a PS=0 may have a greater benefit from treatment intensification (HR=1.38; 95% CI, 0.99–1.93, p=.063). Conclusions: This pooled data analysis indicates that combination of gemcitabine with a platinum analog such as oxaliplatin or cisplatin significantly improves PFS and OS as compared to single-agent gemcitabine in APC. [Table: see text]
What factors affect long-term survival after responding to gefitinib in advanced non-small cell lung cancer? Real-world evidence.
Authors: Yoshiko Takeuchi, Fumio Imamura, Satoshi Morita, Masahide Mori, Kiyoshi Komuta, Takashi Kijima, Yoshinobu Namba, Kazumi Nishino, Suguru Yamamoto, Ryo Takahashi, Yukie Nakazawa, Seigo Minami, Yoshitaka Ogata, Atsushi Kumanogoh
Journal: Journal of Clinical Oncology (2012)

e18007 Background: After gefitinib was approved in July 2002, we experience long-term surviving patients in the actual clinical setting. However, it is not clear how the factors or treatment strategy are contributing to the long-term surviving patients.We evaluated the effects of clinical backgrounds and treatment histories on overall survival (OS). Methods: We extracted information on advanced NSCLC patients with the following inclusion criteria from the medical records: 1) Patients who were diagnosed by October 2010 and treated with gefitinib after July 2002: 2) Performance status (PS) 0 – 2, 3) PR, CR, or long SD (6 months or more) by gefitinib treatment : 4) Patients who had not received curative surgical operation or curative radiation therapy. Primary objective is to evaluate survival time of the patients who responded to gefitinib and clarify the relationship between clinical factors and survival time. We also conducted “Dynamic Treatment Regimen Analysis (DTRA)” to explore key treatment regimen and sequence of regimens contributing to long-term survival. Results: The medical records of total of 275 patients were extracted. 44% (122/275) were EGFR mutation examined and 93% (114/122) has shown the EGFR mutation positive. The mean age was 65 years, 72% (198/275) were women, 66% (182/275) were non-smokers, and 90% (247/275) had adenocarcinoma histology. 20% (54/275) and 21% (58/275) underwent re-administration and beyond PD administration of gefitinib respectively. Median survival time (MST) was 615 day (95% C.I; 519-691). 10% patients survived for more than 5 years. The multivariate Cox analysis demonstrated that sex (p=0.0108) and gefitinib re-administration (p=0.0012) were significant independent factors for long-term OS. Grade 3/4 interstitial lung disease, skin, diarrhea, and liver dysfunction were observed in 1.5%, 4.4%, 1.1%, and 13.1% of the patients, respectively. Conclusions: This study suggests that sex and gefitinib re-administration, may have significant affects on OS in long survivors after responding gefitinib treatment.
Determinants of downloads and citations for articles published in Intensive Care Medicine
Authors: J. F. Timsit, G. Citerio, M. Lavilloniere, A. Perner, S. Ruckly, J. Bakker, M. Bassetti, D. Benoit, J. R. Curtis, G. S. Doig, M. Herridge, S. Jaber, L. Papazian, M. J. Peters, P. Singer, M. Smith, M. Soares, A. Torres, A. Vieillard-Baron, E. Azoulay
Journal: Intensive Care Medicine (2019)
AGE- AND GENDER-RELATED DIFFERENCES IN PLAQUE COMPOSITION OF CORONARY LESIONS: AN OPTICAL COHERENCE TOMOGRAPHY STUDY
Authors: Toshimitsu Sato, Yoshiyasu Minami, Kiyoshi Asakura, Masahiro Katamine, Ayami Kato, Aritomo Katsura, Yusuke Muramatsu, Ryota Kakizaki, Teruyoshi Nemoto, Kazuhiro Fujiyoshi, Takuya Hashimoto, Ryo Kameda, Kentaro Meguro, Takao Shimohama, Junya Ako
Journal: Journal of the American College of Cardiology (2020)
CGE20-070: Gene Silencing: Another Mechanism of Resistance?
Authors: Jacob J. Adashek, Shumei Kato, Rahul Parulkar, Christopher W. Szeto, J. Zachary Sanborn, Charles J. Vaske, Stephen C. Benz, Sandeep K. Reddy, Razelle Kurzrock
Journal: Journal of the National Comprehensive Cancer Network (2020)
Doctor who tried to smuggle ecstasy tablets into UK is struck off while in French prison
Authors: Clare Dyer
Journal: BMJ (2020)

A doctor who was caught by French customs while trying to smuggle 123 162 MDMA (ecstasy) tablets to the UK has been struck off the UK medical register.

Shoaib Ahmad, who qualified in 2005 from the University of London, is now in a French prison serving a six year sentence. He was stopped while driving into France from Belgium in August 2017. Officers found four bags of pills in the boot of his UK registered Jaguar, together weighing 45 kg.

Documents in the car revealed that he had used Airbnb to rent a holiday …
Vitamin Supplementation in Elderly Persons—Reply
Authors: Judith M. Graat, Evert G. Schouten, Frans J. Kok
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Disparities in first-course treatment of non-small cell lung cancer among different hospital types in the United States.
Authors: Abhishek Singla, Avyakta Kallam, Jayanth Adusumalli, Mahmoud Abu Hazeem, Peter T. Silberstein
Journal: Journal of Clinical Oncology (2013)

6568 Background: Treatment of non-small cell lung cancer (NSCLC) involves surgery, chemotherapy and radiation therapy in various combinations depending upon stage. This study compares disparities in the 1st course treatment given to NSCLC patients amongst different hospital types. Methods: We analyzed National Cancer Data Base for differences in 1st course treatment received for NSCLC amongst 3 hospital categories- Community hospitals (facilities which diagnose and/or treat 100-649 cancer cases annually), Comprehensive Community Hospitals (facilities which diagnose and/or treat 650 or more) and Teaching/Research Hospitals (facilities associated with university medical schools or designated as Comprehensive Cancer Care Programs by National Cancer Institute). Chi square test was used for statistical analysis. Results: 975,229 patients with NSCLC received treatment in 1,399 U.S. hospitals between 2000 and 2010. 71%, 81% and 84% of patients presenting to Community, Comprehensive and Teaching/Research hospitals received 1st course treatment at those centers. Surgery was done in 64%, 77% and 81% of stage I; 52%, 62% and 71% of stage II and 16%, 20% and 27% of stage III patients treated by Community, Comprehensive and Teaching/Research hospitals respectively (p&lt;0.001 for all comparisons) (Table). Also, chemotherapy was given as a part of 1st course treatment in 37%, 30% and 22% of stage II patients treated by these hospitals respectively (p&lt;0.001 for all comparisons). Conclusions: Significant disparities exist in treatment of NSCLC amongst different hospital types. Patients treated at research/teaching hospitals hospital are more likely to receive surgery as 1st line compared to Community and Comprehensive hospital for stage I to III NSCLC. [Table: see text]
IMPACT OF HEART FAILURE HOSPITALIZATION ON GUIDELINE-DIRECTED MEDICAL THERAPY PRESCRIBING PATTERNS AMONG PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION: AN ANALYSIS FROM CHAMP-HF
Authors: Pratyaksh Srivastava, Adam DeVore, Anne Hellkamp, Laine Thomas, Nancy M. Albert, Javed Butler, J. Herbert Patterson, John A. Spertus, Fredonia Williams, Carol I. Duffy, Adrian Hernandez, Gregg C. Fonarow
Journal: Journal of the American College of Cardiology (2020)
Abstract 17355: Myocardial Infarction Causes Both Structural and Functional Remodeling in Cardiac Neurons of the Inferior Vagal (Nodose) Ganglia: Implications for Mechanisms Behind Parasympathetic Withdrawal in Heart Disease
Authors: Siamak Salavatian, Naoko Yamaguchi, David Hamon, Michael C. Fishbein, Jeffrey L. Ardell, Kalyanam Shivkumar, Marmar Vaseghi
Journal: Circulation (2017)

Introduction: Mechanisms behind parasympathetic withdrawal due to myocardial infarction (MI) are unknown. Afferent neurons in the inferior vagal (nodose) ganglia transduce cardiac function beat by ...
Pulmonary symptoms and their importance to patients with non-small cell lung cancer undergoing second- and third-line chemotherapy.
Authors: Susan Magasi, Karen Kaiser, Rajiv Mallick, David Cella
Journal: Journal of Clinical Oncology (2012)

9056 Background: As new cancer therapies are developed, it is important to evaluate their efficacy based not only on survival outcomes but also meaningful patient benefit in terms of symptoms and concerns that are important to patients. The purpose of this study of patients undergoing 2 nd /3 rd line chemotherapy for non-small cell lung cancer (NSCLC) was to characterize pulmonary symptoms and the importance patients place on these symptoms, as a part of assessing the content validity of the Pulmonary Symptom Index (PSI) of the Functional Assessment of Cancer Therapy – Lung (FACT-L). Methods: We conducted semi-structured thematic interviews with 20 stage III/IV NSCLC patients undergoing 2 nd or 3 rd line treatment. Interviews included open elicitation of NSCLC symptoms and their functional impact, and participant ratings of the relative importance of pulmonary symptoms. Results: Mean age was 62 years (range 30-79); 80% had non-squamous histology, and 30% had co-morbid COPD. While participants described a range of symptom experiences and severity, a core set of pulmonary symptoms emerged - shortness of breath (reported by 16/20, 13/20 rated as very important), cough (reported by 14/20, 10/20 rated as very important), and chest tightness (reported by 15/20, 9/20 rated as very important); these matched key symptoms in the PSI. Symptom importance ratings were influenced by the functional impact they had upon patient ability to perform valued roles and responsibilities. Patients described diverse coping strategies including breaking down activities into manageable tasks, priority setting, physical assistance, emotional support, and health promoting changes in diet and exercise. Ninety percent (18/20) of participants reported tiredness or fatigue; most said it was “very important.” A quarter (5/20) of the participants reported having no pulmonary symptoms. Conclusions: These results in NSCLC patients undergoing 2 nd /3 rd line treatment support the importance, relevance, and impact of core pulmonary symptoms included in the PSI and offer initial evidence that its content may constitute a key element of patient benefit in evaluating the efficacy of new cancer therapies.
Assessment of the Role of IQ in Associations Between Population Density and Deprivation and Nonaffective Psychosis
Authors: Gemma Lewis, Jennifer Dykxhoorn, Håkan Karlsson, Golam M. Khandaker, Glyn Lewis, Christina Dalman, James B. Kirkbride
Journal: JAMA Psychiatry (2020)

Being born or raised in more densely populated or deprived areas is associated with increased risk of nonaffective psychosis in adulthood, but few studies to date have examined the role of general cognitive ability in these associations.To investigate whether lower IQ contributed to the association between population density or deprivation and nonaffective psychosis (mediation) and whether these associations were stronger in people with lower IQ (effect modification).This prospective cohort study evaluated a population-based sample of men born in Sweden from January 1, 1982, to December 31, 1988, and conscripted into military service at 18 years of age. Data were collected from January 1, 1982, to December 31, 2016, and analyzed from May 1 to December 31, 2018.Continuous measures of small area-level population density (persons per square kilometer) and socioeconomic deprivation at birth. Deprivation was based on area-level social, criminal, and unemployment data. IQ was assessed during conscription at 18 years of age (mean [SD] IQ, 100 [15]).First diagnosis of International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, nonaffective psychosis from 18 years of age until December 31, 2016, recorded in the National Patient Register.The study sample included a total of 227 429 men who were classified as at risk of psychosis from 18 years of age until the end of follow-up. Of these, 1596 men (0.7%) were diagnosed with nonaffective psychosis. After adjustments for confounders, odds of nonaffective psychosis increased per 1-SD increase in population density (odds ratio [OR], 1.07; 95% CI, 1.04-1.14) and deprivation (OR, 1.09; 95% CI, 1.02-1.13) at birth. IQ was negatively associated with deprivation after adjustments (effect estimate per 1-SD increase in deprivation: -0.70 points; 95% CI, -0.78 to -0.62 points) but not with population density. In mediation analyses, based on the potential outcome framework, 23% (95% CI, 17%-49%) of the total effect of deprivation on nonaffective psychosis was mediated by IQ. IQ did not modify associations between deprivation or population density and nonaffective psychosis.These findings suggest that being born in more deprived neighborhoods may partly increase risk of nonaffective psychosis through subsequent effects on cognitive development, consistent with the wider literature on neurodevelopmental delays associated with psychotic disorder. Identifying factors in deprived environments that give rise to this process could inform public health strategies to prevent nonaffective psychosis.
ACUTE HEART TRANSPLANTATION: A VIABLE ALTERNATIVE IN CARDIOGENIC SHOCK PATIENTS WITH POST-INFARCTION VENTRICULAR SEPTAL DEFECTS
Authors: Alexandra M. Sanchez, Nicholas Ghiloni, Hardik M. Bhansali, Nader Hanna, Luis Alonso Hernandez Mejia, Kevin Leung, Kenneth Fromkin, Craig Asher, Roberto J. Cubeddu, Cedric Sheffield, Elsy Navas
Journal: Journal of the American College of Cardiology (2020)
POSTOPERATIVE ACUTE HEART FAILURE IS AN INDEPENDENT PREDICTOR OF LONG-TERM MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Zhaodong Guo, Jin Liu, Guoli Sun, Yibo He, Feier Song, Shiqun Chen, Li Lei, Bowen Liu, Liwei Liu, Guanzhong Chen, Pengyuan Chen, Jianbin Zhao, Dengxuan Wu, Jiyan Chen, Yong Liu, Ning Tan
Journal: Journal of the American College of Cardiology (2020)
Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?
Authors: Lin-Lu Ma, Yun-Yun Wang, Zhi-Hua Yang, Di Huang, Hong Weng, Xian-Tao Zeng
Journal: Military Medical Research (2020)

Methodological quality (risk of bias) assessment is an important step before study initiation usage. Therefore, accurately judging study type is the first priority, and the choosing proper tool is also important. In this review, we introduced methodological quality assessment tools for randomized controlled trial (including individual and cluster), animal study, non-randomized interventional studies (including follow-up study, controlled before-and-after study, before-after/ pre-post study, uncontrolled longitudinal study, interrupted time series study), cohort study, case-control study, cross-sectional study (including analytical and descriptive), observational case series and case reports, comparative effectiveness research, diagnostic study, health economic evaluation, prediction study (including predictor finding study, prediction model impact study, prognostic prediction model study), qualitative study, outcome measurement instruments (including patient - reported outcome measure development, content validity, structural validity, internal consistency, cross-cultural validity/ measurement invariance, reliability, measurement error, criterion validity, hypotheses testing for construct validity, and responsiveness), systematic review and meta-analysis, and clinical practice guideline. The readers of our review can distinguish the types of medical studies and choose appropriate tools. In one word, comprehensively mastering relevant knowledge and implementing more practices are basic requirements for correctly assessing the methodological quality.
7P Proteomics plus RNA-seq in advanced melanoma samples treated with anti-PD1 immunotherapy unravel resistance mechanisms
Authors: G. Prado Vázquez, A. Gámez Pozo, L. Trilla Fuertes, A. Zapater Moros, E. López Camacho, R. López Vacas, M. Díaz Almirón, P. Zamora, J.A. Fresno Vara, E. Espinosa
Journal: Annals of Oncology (2020)